Theranostics for Triple-Negative Breast Cancer

被引：22

作者：

Choi, Hyeryeon ^{[1
]}

Kim, Kwangsoon ^{[2
]}

机构：

[1] Eulji Univ, Eulji Med Ctr, Dept Surg, Sch Med, Seoul 01830, South Korea

[2] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 06591, South Korea

来源：

DIAGNOSTICS | 2023年 / 13卷 / 02期

关键词：

theranostics; nanomedicine; immunotherapy; breast cancer; PEMBROLIZUMAB PLUS CHEMOTHERAPY; GAMMA-SECRETASE INHIBITORS; POLYMERIC MICELLES; CARBON NANOTUBES; DOUBLE-BLIND; ANTITUMOR-ACTIVITY; QUANTUM DOTS; DRUG; DELIVERY; CELLS;

D O I：

10.3390/diagnostics13020272

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.

引用

页数：13

共 101 条

[31] Precision Medicine: From Science To Value [J].

Ginsburg, Geoffrey S. ;

Phillips, Kathryn A. .

HEALTH AFFAIRS, 2018, 37 (05) :694-701

[32] Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer [J].

Gonzalez-Angulo, Ana M. ;

Timms, Kirsten M. ;

Liu, Shuying ;

Chen, Huiqin ;

Litton, Jennifer K. ;

Potter, Jennifer ;

Lanchbury, Jerry S. ;

Stemke-Hale, Katherine ;

Hennessy, Bryan T. ;

Arun, Banu K. ;

Hortobagyi, Gabriel N. ;

Do, Kim-Anh ;

Mills, Gordon B. ;

Meric-Bernstam, Funda .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1082-1089

[33] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[34] Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin [J].

Hastak, Kedar ;

Alli, Elizabeth ;

Ford, James M. .

CANCER RESEARCH, 2010, 70 (20) :7970-7980

[35] Classification of triple-negative breast cancers based on Immunogenomic profiling [J].

He, Yin ;

Jiang, Zehang ;

Chen, Cai ;

Wang, Xiaosheng .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37

[36] The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings [J].

Helleday, Thomas .

MOLECULAR ONCOLOGY, 2011, 5 (04) :387-393

[37] PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow [J].

Hopkins, Todd A. ;

Ainsworth, William B. ;

Ellis, Paul A. ;

Donawho, Cherrie K. ;

DiGiammarino, Enrico L. ;

Panchal, Sanjay C. ;

Abraham, Vivek C. ;

Algire, Mikkel A. ;

Shi, Yan ;

Olson, Amanda M. ;

Johnson, Eric F. ;

Wilsbacher, Julie L. ;

Maag, David .

MOLECULAR CANCER RESEARCH, 2019, 17 (02) :409-419

[38] Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors [J].

Huang, Xiumei ;

Motea, Edward A. ;

Moore, Zachary R. ;

Yao, Jun ;

Dong, Ying ;

Chakrabarti, Gaurab ;

Kilgore, Jessica A. ;

Silvers, Molly A. ;

Patidar, Praveen L. ;

Cholka, Agnieszka ;

Fattah, Farjana ;

Cha, Yoonjeong ;

Anderson, Glenda G. ;

Kusko, Rebecca ;

Peyton, Michael ;

Yan, Jingsheng ;

Xie, Xian-Jin ;

Sarode, Venetia ;

Williams, Noelle S. ;

Minna, John D. ;

Beg, Muhammad ;

Gerber, David E. ;

Bey, Erik A. ;

Boothman, David A. .

CANCER CELL, 2016, 30 (06) :940-952

[39] Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer [J].

Inoue, Satoshi ;

Patil, Rameshwar ;

Portilla-Arias, Jose ;

Ding, Hui ;

Konda, Bindu ;

Espinoza, Andres ;

Mongayt, Dmitriy ;

Markman, Janet L. ;

Elramsisy, Adam ;

Phillips, H. Westley ;

Black, Keith L. ;

Holler, Eggehard ;

Ljubimova, Julia Y. .

PLOS ONE, 2012, 7 (02)

[40] Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer [J].

Jain, Anjali ;

Mahira, Shaheen ;

Majoral, Jean-Pierre ;

Bryszewska, Maria ;

Khan, Wahid ;

Ionov, Maksim .

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2019, 107 (09) :1933-1944

← 1 2 3 4 5 6 7 8 9 10 →